Category: Guest content

Biotechnology in Countries Beginning with “I” – Part 9: Iran

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Looking beyond the landmark nuclear deal, Iranian media sources are trumpeting the Islamic State’s prowess in biotechnology.  So how does Iran really measure up – globally and compared to […]


The Paradox of Pharmaceutical Hyperconnectivity

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As we head into the dog days of summer I continue to reflect on the  recent DIA and BIO annual meetings held in mid-June. At both events I was […]


Adventures in Binational Biopharma: Innovative Medicines “Made in India”

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As a Non-NRI, I did not plan to launch a bio-pharmaceutical start-up company in India on my own. That would be a little crazy. Instead I took a […]


Cancer’s Science Revolution Comes on Little Cat Feet

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Back when I wrote ISO A Scientific Revolution in Cancer Research in April of 2013, I truly did not expect to be able to greet the revolution by […]


Expand Your Cell-Based Protein Manufacturing with Hollow Fiber Bioreactors

This is a guest post from Halina Zakowicz, Marketing Specialist at Biovest International, Inc. Do you have a response to Halina’s post? Respond in the comments section below. Scaling up cell culture production can be a tricky proposition. Generating large amounts of cell-secreted proteins is labor-intensive when utilizing traditional cell culture methods. Quality and yields […]


Biotechnology in Countries Starting with “I” – Part 7: India

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. For the next chapter in this continuing series, let’s turn back to India and the draft National IPR Policy currently under debate in New Delhi. A great deal […]


Unlocking the Mystery of Angel Investment

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in […]


Key Elements of Succession Planning In Bioscience

This is a guest post from Steve McLaughlin, Managing Partner and Founder of US BioSearch. Do you have a response to Steve’s post? Respond in the comments section below. Effective succession plans involve a combination of many choices and decisions that are distinctive to each, specific company. Bioscience companies also present their own, unique challenges, as […]


Leadership Skills in the Biotech Start-Up

This is a guest post from Isabela Oliva. Do you have a response to Isabela’s post? Respond in the comments section below. How to survive the expected and unexpected challenges of the start-up lifecycle in the biotechnology business A major difference between biotechnology and information technology ventures is the time it takes to bring a product […]


What changes will India’s next Prime Minister bring to India’s Innovative Life Sciences? (Part 2)

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. India’s new Prime Minister  Narendra Modi has asked Ministers to set ambitious targets for the first 100 days of government,. While the BJP Party Manifesto calls for implementation […]